ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Original text here LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP).
Read

International Symposium on Usher Syndrome 2018

Last week the International Symposium on Usher Syndrome was held in Mainz. It was a 3-day event, we only attended the patient’s symposium as I was afraid that the 2 scientific days would be too complicated to follow anyway (and I would be braindead before the patient program even started…).
Read